跳至主要内容
临床试验/ISRCTN15718519
ISRCTN15718519进行中(未招募)Unknown

Supporting uptake of risk-reducing medications and minimising treatment discontinuation: a process evaluation

Peter MacCallum Cancer Centre0 个研究点目标入组 250 人开始时间: 2024年5月2日最近更新:
适应症

试验速览

阶段
Unknown
状态
进行中(未招募)
发起方
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Eligibility Criteria for clients:
  • 1. Female.
  • 2. Age between 20 and 70 years old
  • 3. Residual lifetime breast cancer risk of at least 20% or a 10-year risk of at least 5%, or history of lobular carcinoma in situ (LCIS) or atypical hyperplasia, or previous thoracic irradiation
  • 4. Does not require germline genetic testing to further clarify the risk
  • 5. Does not carry a pathogenic variant in a high-risk breast cancer predisposition gene and is not an untested 1st-degree relative for carriers
  • 6. No history of invasive breast cancer or ductal carcinoma in situ (DCIS)
  • 7. No history of bilateral mastectomy
  • 8. No prior or current use of breast cancer prevention medications
  • Eligibility for clinicians:
  • Clinicians working in clinics from which eligible clients could be referred

排除标准

  • Not meeting the inclusion criteria

研究者

发起方
Peter MacCallum Cancer Centre

相似试验

Evaluation of a clinical service to support the... | 临床试验